A Biotherapeutics program, starting from discovery through commercial manufacturing, has a lifespan of decades, and must be built on a strong and technologically deep manufacturing
platform. The speed of each stage of development and the costs of continuing commercial production depends not only on the efficacy of the product and complexity of the indication
but also on the specified manufacturing process. A well optimized manufacturing platform is composed of a well characterized and documented host cell line, a one-size-fits-all expression vector that gives high yield and reliable stable expression, a clone screening platform that can rapidly screen for titer and Critical Quality Attributes, and an accompanying process that transfers easily between facilities and to large scale.
In this webinar, Divya Goel, VP of Business Development at Celltheon, will discuss the challenges in drug developability, cell line development and large-scale manufacturing. Learn why the CELLTHEON SMART™ is the platform of choice to build your next blockbuster biotherapeutics programs.
- Industry leading transient expression that uses same host cell line as manufacturing cell line.
- Express all types of proteins from simple mAbs to DEPs
- Pool titers of 5-8 g/L and clone titers of 8-12 g/L
Celltheon does not stop innovating: future proof your choice of platform with CELLTHEON SMART™
Speaker: Divya Goel
VP of Business Development, CELLTHEON
As the VP of Business Development, Divya oversees platform development and technology licensing for Celltheon. As a bioprocess engineer by training, Divya is not only involved in external facing business opportunities, she also works with the technical staff to evaluate new bioprocessing technologies and develop efficient workflows that can be leveraged by the greater Pharmaceutical Industry. Divya regularly attends scientific conferences to present the Celltheon SMART Technology™ platform and discuss other advances that Celltheon has made in bioprocessing.
Divya holds a BS in Biology from Drexel University and a Master’s in Business and Science (MBS) from Keck Graduate Institute in Bioprocess Engineering and Business. Since joining Celltheon, many of the client molecules she has overseen have advanced into late stages of development. Divya is committed to overseeing the application of Celltheon’s novel technologies to develop high titer, high quality products and ensuring seamless tech transfer.